

19106765D

## SENATE BILL NO. 1692

## AMENDMENT IN THE NATURE OF A SUBSTITUTE

(Proposed by the House Committee on Agriculture, Chesapeake and Natural Resources  
on February 13, 2019)

(Patron Prior to Substitute—Senator Ruff)

A BILL to amend and reenact §§ 3.2-4112, 3.2-4113, 3.2-4114, 3.2-4114.2, 3.2-4115, 3.2-4116, 3.2-4118, 3.2-4119, 18.2-247, 54.1-3401, as it is currently effective and as it shall become effective, 54.1-3408.3, and 54.1-3446 of the Code of Virginia and to repeal §§ 3.2-4114.1 and 3.2-4117 of the Code of Virginia, relating to industrial hemp.

Be it enacted by the General Assembly of Virginia:

1. That §§ 3.2-4112, 3.2-4113, 3.2-4114, 3.2-4114.2, 3.2-4115, 3.2-4116, 3.2-4118, 3.2-4119, 18.2-247, 54.1-3401, as it is currently effective and as it shall become effective, 54.1-3408.3, and 54.1-3446 are amended and reenacted as follows:

§ 3.2-4112. Definitions.

As used in this chapter, unless the context requires a different meaning:

"Cannabis sativa product" means a product made from any part of the plant *Cannabis sativa*, including seeds thereof and any derivative, extract, cannabinoid, isomer, acid, salt, or salt of an isomer, whether growing or not, with a concentration of tetrahydrocannabinol that is greater than that allowed by federal law.

"Deal" means to buy industrial hemp grown in compliance with state or federal law and to sell such industrial hemp to a person who (i) processes industrial hemp in compliance with state or federal law or (ii) sells industrial hemp to a person who processes industrial hemp in compliance with state or federal law.

"Dealer" means any person who is registered pursuant to subsection A of § 3.2-4115 to deal in industrial hemp. "Dealer" does not include (i) a grower, (ii) a processor, or (iii) any person who buys industrial hemp for personal use or retail sale in Virginia.

"Dealership" means the location at which a dealer stores or intends to store the industrial hemp in which he deals.

"Grow" means to plant, cultivate, or harvest a plant or crop.

"Grower" means any person registered pursuant to subsection A of § 3.2-4115 to grow industrial hemp.

"Hemp product" means a any finished product made from that is otherwise lawful and that contains industrial hemp, including rope, building materials, automobile parts, animal bedding, animal feed, cosmetics, oil containing an industrial hemp extract, or food or food additives for human consumption.

"Higher education industrial hemp research program" means a research program established pursuant to subsection A of § 3.2-4114.1.

"Industrial hemp" means all parts and varieties any part of the plant *Cannabis sativa*, including seeds thereof and any derivative, extract, cannabinoid, isomer, acid, salt, or salt of an isomer, whether growing or not, that contain with a concentration of tetrahydrocannabinol that is no greater than that allowed by federal law.

"Process" means to convert industrial hemp into a marketable form hemp product.

"Processor" means a person registered pursuant to subsection A of § 3.2-4115 to process industrial hemp.

"Process site" means the location at which a processor processes or intends to process industrial hemp.

"Production field" means the land or area on which a grower is growing or intends to grow industrial hemp.

"Virginia industrial hemp research program" means the research program established pursuant to subsection B of § 3.2-4114.1.

§ 3.2-4113. Production of industrial hemp lawful.

A. It is lawful for a grower or his agent to grow, a dealer or his agent to deal in, or a processor or his agent to process industrial hemp in the Commonwealth for any lawful purpose, including the manufacture of a hemp product or scientific, agricultural, or other research related to other lawful applications for industrial hemp. No grower or his agent, dealer or his agent, or processor or his agent shall be prosecuted under § 18.2-247, 18.2-248, 18.2-248.01, 18.2-248.1, 18.2-250, or 18.2-250.1 for the possession, growing, dealing, or processing of industrial hemp. In any complaint, information, or indictment, and in any action or proceeding brought for the enforcement of any provision of Article 1 (§ 18.2-247 et seq.) of Chapter 7 of Title 18.2 or the Drug Control Act (§ 54.1-3400 et seq.), it shall not be necessary to negate any exception, excuse, proviso, or exemption contained in this chapter or the

60 Drug Control Act, and the burden of proof of any such exception, excuse, proviso, or exemption shall  
61 be on the defendant.

62 B. Nothing in this chapter shall be construed to authorize any person to violate any federal law or  
63 regulation. If any part of this chapter conflicts with a provision of federal law relating to industrial  
64 hemp, the federal provision shall control to the extent of the conflict.

65 C. No person shall be prosecuted under § 18.2-247, 18.2-248, 18.2-248.01, 18.2-248.1, 18.2-250, or  
66 18.2-250.1 for the involuntary growth of industrial hemp through the inadvertent natural spread of seeds  
67 or pollen as a result of proximity to a production field, *dealership*, or process site.

68 **§ 3.2-4114. Regulations.**

69 The Board may adopt regulations pursuant to this chapter as necessary to register persons to grow,  
70 *deal in*, or process industrial hemp or implement the provisions of this chapter.

71 **§ 3.2-4114.2. Authority of Commissioner; notice to law enforcement; report.**

72 A. The Commissioner may charge a nonrefundable fee not to exceed \$50 for ~~(i)~~ any application for  
73 registration or renewal of registration allowed under this chapter ~~and (ii). The Commissioner may charge~~  
74 *a nonrefundable fee for the* tetrahydrocannabinol testing allowed under this chapter. All fees collected by  
75 the Commissioner shall be deposited in the state treasury.

76 B. ~~The Commissioner may establish a minimum size for a production field that shall qualify a person~~  
77 ~~for a Virginia industrial hemp research program grower registration.~~

78 C. The Commissioner shall notify the Superintendent of State Police of the locations of all industrial  
79 hemp production fields, *dealerships*, and process sites.

80 ~~D.~~ C. The Commissioner shall forward a copy or appropriate electronic record of each registration  
81 issued by the Commissioner under this chapter to the chief law-enforcement officer of the county or city  
82 where industrial hemp will be grown, *dealt*, or processed.

83 E. D. The Commissioner shall be responsible for monitoring the industrial hemp grown, *dealt*, or  
84 processed by a person registered pursuant to subsection A of § 3.2-4115 and shall provide for random  
85 testing of the industrial hemp, at the cost of the grower, *dealer*, or processor, for compliance with  
86 tetrahydrocannabinol limits and for other appropriate purposes established pursuant to § 3.2-4114. In  
87 addition to any routine inspection and sampling, the Commissioner may inspect and sample the  
88 industrial hemp at any production field, *dealership*, or process site during normal business hours without  
89 advance notice if he has reason to believe a violation of this chapter is occurring or has occurred.

90 F. E. The Commissioner may require a grower, *dealer*, or processor to destroy, at the cost of the  
91 grower, *dealer*, or processor and in a manner approved of and verified by the Commissioner, any  
92 *Cannabis sativa* that the grower grows ~~or, in which the dealer deals, or that the processor processes~~ that  
93 has been tested and is found to have a concentration of tetrahydrocannabinol that is greater than that  
94 allowed by federal law, *or any Cannabis sativa product that the processor produces*.

95 F. Notwithstanding the provisions of subsection E, if the provisions of subdivisions 1 and 2 are  
96 included in a plan that (i) is submitted by the Department pursuant to § 10113 of the federal Agriculture  
97 Improvement Act of 2018, P.L. 115-334, (ii) requires the Department to monitor and regulate the  
98 production of industrial hemp in the Commonwealth, and (iii) is approved by the U.S. Secretary of  
99 Agriculture:

100 1. The Commissioner may require a grower, *dealer*, or processor to destroy, at the cost of the  
101 grower, *dealer*, or processor and in a manner approved of and verified by the Commissioner, any  
102 *Cannabis sativa* that the grower grows, in which the dealer deals, or that the processor processes that  
103 has been tested and is found to have a concentration of tetrahydrocannabinol that is greater than 0.6  
104 percent.

105 2. If such a test of *Cannabis sativa* indicates a concentration of tetrahydrocannabinol that is greater  
106 than 0.6 percent but less than one percent, the Commissioner shall allow the grower, *dealer*, or  
107 processor to request that the *Cannabis sativa* be sampled and tested again before he requires its  
108 destruction.

109 G. The Commissioner ~~may~~ shall advise the Attorney General of the United States and the  
110 Superintendent of State Police or the chief law-enforcement officer of the appropriate county or city  
111 when, with a culpable mental state greater than negligence, a grower grows, a *dealer deals in*, or a  
112 processor processes any *Cannabis sativa* with a concentration of tetrahydrocannabinol that is greater than  
113 that allowed by federal law *or a processor produces a Cannabis sativa product*.

114 H. The Commissioner may pursue any permits or waivers from the U.S. Drug Enforcement  
115 Administration or appropriate federal agency that he determines to be necessary for the advancement of  
116 a higher education industrial hemp research program ~~or the Virginia industrial hemp research program~~  
117 *industry*.

118 I. The Commissioner may cooperatively seek funds from public and private sources to implement a  
119 higher education industrial hemp research program ~~or the Virginia industrial hemp research program~~  
120 *establish a corrective action plan to address a negligent violation of any provision of this chapter*.

121 J. By December 1 of each year, the Commissioner shall report on the status and progress of any

higher education industrial hemp research program and the Virginia industrial hemp research program to the Governor and to the General Assembly and shall submit such report for publication as a report document as provided in the procedures of the Division of Legislative Automated Systems for the processing of legislative documents and reports.

**§ 3.2-4115. Issuance of registrations.**

A. The Commissioner shall establish a registration program to allow a person to grow, *deal in*, or process industrial hemp in the Commonwealth in a controlled fashion solely and exclusively as part of a higher education industrial hemp research program or the Virginia industrial hemp research program.

B. Any person seeking to grow, *deal in*, or process industrial hemp as part of a higher education industrial hemp research program or the Virginia industrial hemp research program in the Commonwealth shall apply to the Commissioner for a registration on a form provided by the Commissioner. At a minimum, the application shall include:

1. The name and mailing address of the applicant;

2. The legal description and geographic data sufficient for locating (i) the land on which the applicant intends to grow industrial hemp or, (ii) *the site at which the applicant intends to deal in industrial hemp*, or (iii) the site at which the applicant intends to process industrial hemp. A registration shall authorize industrial hemp growth, *dealing in*, or processing only at the location specified in the registration;

3. A signed statement indicating whether the applicant has ever been convicted of a felony. A person with a prior felony drug conviction within 10 years of applying for a registration under this section shall not be eligible to be registered;

4. Written consent allowing the sheriff's office, police department, or Department of State Police, if a registration is ultimately issued to the applicant, to enter the premises on which the industrial hemp is grown, *dealt in*, or processed to conduct physical inspections of the industrial hemp and to ensure compliance with the requirements of this chapter. No more than two physical inspections shall be conducted under this subdivision per year, unless a valid search warrant for an inspection has been issued by a court of competent jurisdiction;

5. If the applicant intends to participate in a higher education industrial hemp research program, documentation of an agreement between an institution of higher education and the applicant that states that the applicant, if registered pursuant to subsection A, will be a participant in the higher education industrial hemp research program managed by that institution of higher education;

6. Written consent allowing the Commissioner or his designee to enter the premises on which the industrial hemp is grown, *dealt in*, or processed to conduct inspections and sampling of the industrial hemp to ensure compliance with the requirements of this chapter;

7. If the applicant intends to participate in the Virginia industrial hemp research program, a 6. A statement of the approximate square footage or acreage of the location he intends to use as a production field, *dealership*, or process site and a description of the research he plans to conduct to advance the industrial hemp industry;

8. 7. Any other information required by the Commissioner; and

9. 8. The payment of a nonrefundable application fee, in an amount set by the Commissioner not to exceed \$50.

C. Each registration issued pursuant to this section shall be valid for a period of one year from the date of issuance and may be renewed in successive years. Each annual renewal shall require the payment of a registration renewal fee, in an amount set by the Commissioner not to exceed \$50.

D. All records, data, and information filed in support of a registration application submitted pursuant to this section shall be considered proprietary and excluded from the provisions of the Virginia Freedom of Information Act (§ 2.2-3700 et seq.).

**§ 3.2-4116. Registration conditions.**

A. A person shall obtain a registration pursuant to subsection A of § 3.2-4115 prior to growing, *dealing in*, or processing any industrial hemp in the Commonwealth.

B. A person issued a registration pursuant to subsection A of § 3.2-4115 shall:

1. Maintain records that reflect compliance with this chapter and with all other state or federal laws regulating the growing, *dealing in*, or processing of industrial hemp;

2. Retain all industrial hemp growing, *dealing*, or processing records for at least three years;

3. Allow his production field, *dealership*, or process site to be inspected by and at the discretion of the Commissioner or his designee, the Department of State Police, or the chief law-enforcement officer of the locality in which the production field or *dealership* or process site exists;

4. Allow the Commissioner or his designee to monitor and test the grower's, *dealer's*, or processor's industrial hemp for compliance with tetrahydrocannabinol levels and for other appropriate purposes established pursuant to § 3.2-4114, at the cost of the grower, *dealer*, or processor; and

5. If the person is a participant in a higher education industrial hemp research program, maintain a

183 current written agreement with an institution of higher education that states that the grower or processor  
184 is a participant in the higher education industrial hemp research program managed by that institution of  
185 higher education;

186 6. If required by the Commissioner, destroy, at the cost of the grower, *dealer*, or processor and in a  
187 manner approved of and verified by the Commissioner, any Cannabis sativa that the grower grows, *the*  
188 *dealer deals in*, or the processor processes that has been tested and, *following any re-sampling and*  
189 *retesting as authorized pursuant to the provisions of § 3.2-4114.2*, is found to have a concentration of  
190 tetrahydrocannabinol that is greater than that allowed by federal law; ~~and, or any Cannabis sativa~~  
191 *product that the processor produces*

192 7. If the person is a participant in the Virginia industrial hemp research program, by October 1 of  
193 each year, submit a report to the Commissioner regarding his growing or processing activities for the  
194 previous year.

195 **§ 3.2-4118. Forfeiture of industrial hemp grower, dealer, or processor registration; violations.**

196 A. The Commissioner shall deny the application, or suspend or revoke the registration, of any person  
197 who, *with a culpable mental state greater than negligence*, violates any provision of this chapter. The  
198 Commissioner shall provide reasonable notice of an informal fact-finding conference pursuant to  
199 § 2.2-4019 to any person in connection with the denial, suspension, or revocation of a registration.

200 B. If a registration is revoked as the result of an informal hearing, the decision may be appealed, and  
201 upon appeal an administrative hearing shall be conducted in accordance with the Administrative Process  
202 Act (§ 2.2-4000 et seq.). The grower, *dealer*, or processor may appeal a final order to the circuit court  
203 in accordance with the Administrative Process Act.

204 C. ~~The Commissioner may revoke any registration of any grower or processor who has pled guilty~~  
205 ~~to, or been convicted of, a felony. A person issued a registration pursuant to subsection A of § 3.2-4115~~  
206 *who negligently (i) fails to provide a description and geographic data sufficient for locating his*  
207 *production field, dealership, or process site; (ii) grows, deals in, or processes Cannabis sativa with a*  
208 *tetrahydrocannabinol concentration greater than that allowed by federal law; or (iii) produces a*  
209 *Cannabis sativa product shall comply with any corrective action plan established by the Commissioner*  
210 *in accordance with the provisions of subsection E.*

211 D. A person who grows, deals in, or processes industrial hemp and who negligently fails to register  
212 pursuant to subsection A of § 3.2-4115 shall comply with any corrective action plan established by the  
213 Commissioner in accordance with the provisions of subsection E.

214 E. A corrective action plan established by the Commissioner in response to a negligent violation of a  
215 provision of this chapter shall identify a reasonable date by which the person who is the subject of the  
216 plan shall correct the negligent violation and shall require such person to report periodically for not  
217 less than two calendar years to the Commissioner on the person's compliance with the provisions of this  
218 chapter.

219 F. No person who negligently violates the provisions of this chapter three times in a five-year period  
220 shall be eligible to grow, deal in, or process industrial hemp for a period of five years beginning on the  
221 date of the third violation.

222 **§ 3.2-4119. Eligibility to receive tobacco settlement funds.**

223 Industrial hemp growers, *dealers*, or processors registered under this chapter may be eligible to  
224 receive funds from the Tobacco Indemnification and Community Revitalization Fund established  
225 pursuant to § 3.2-3106.

226 **§ 18.2-247. Use of terms "controlled substances," "marijuana," "Schedules I, II, III, IV, V and**  
227 **VI," "imitation controlled substance" and "counterfeit controlled substance" in Title 18.2.**

228 A. Wherever the terms "controlled substances" and "Schedules I, II, III, IV, V and VI" are used in  
229 Title 18.2, such terms refer to those terms as they are used or defined in the Drug Control Act  
230 (§ 54.1-3400 et seq.).

231 B. The term "imitation controlled substance" when used in this article means (i) a counterfeit  
232 controlled substance or (ii) a pill, capsule, tablet, or substance in any form whatsoever which is not a  
233 controlled substance subject to abuse, and:

234 1. Which by overall dosage unit appearance, including color, shape, size, marking and packaging or  
235 by representations made, would cause the likelihood that such a pill, capsule, tablet, or substance in any  
236 other form whatsoever will be mistaken for a controlled substance unless such substance was introduced  
237 into commerce prior to the initial introduction into commerce of the controlled substance which it is  
238 alleged to imitate; or

239 2. Which by express or implied representations purports to act like a controlled substance as a  
240 stimulant or depressant of the central nervous system and which is not commonly used or recognized for  
241 use in that particular formulation for any purpose other than for such stimulant or depressant effect,  
242 unless marketed, promoted, or sold as permitted by the United States Food and Drug Administration.

243 C. In determining whether a pill, capsule, tablet, or substance in any other form whatsoever, is an  
244 "imitation controlled substance," there shall be considered, in addition to all other relevant factors,

comparisons with accepted methods of marketing for legitimate nonprescription drugs for medicinal purposes rather than for drug abuse or any similar nonmedicinal use, including consideration of the packaging of the drug and its appearance in overall finished dosage form, promotional materials or representations, oral or written, concerning the drug, and the methods of distribution of the drug and where and how it is sold to the public.

D. The term "marijuana" when used in this article means any part of a plant of the genus *Cannabis*, whether growing or not, its seeds or resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, or its resin. Marijuana shall not include any oily extract containing one or more cannabinoids unless such extract contains less than 12 percent of tetrahydrocannabinol by weight, or the mature stalks of such plant, fiber produced from such stalk, oil or cake made from the seed of such plant, unless such stalks, fiber, oil or cake is combined with other parts of plants of the genus *Cannabis*. *Marijuana shall not include (i) industrial hemp, as defined in § 3.2-4112, that is possessed by a person registered pursuant to subsection A of § 3.2-4115 or his agent or (ii) a hemp product, as defined in § 3.2-4112, containing a tetrahydrocannabinol concentration of no greater than 0.3 percent that is derived from industrial hemp, as defined in § 3.2-4112, that is grown, dealt, or processed in compliance with state or federal law.*

E. The term "counterfeit controlled substance" means a controlled substance that, without authorization, bears, is packaged in a container or wrapper that bears, or is otherwise labeled to bear, the trademark, trade name, or other identifying mark, imprint or device or any likeness thereof, of a drug manufacturer, processor, packer, or distributor other than the manufacturer, processor, packer, or distributor who did in fact so manufacture, process, pack or distribute such drug.

**§ 54.1-3401. (Effective until July 1, 2020) Definitions.**

As used in this chapter, unless the context requires a different meaning:

"Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a patient or research subject by (i) a practitioner or by his authorized agent and under his direction or (ii) the patient or research subject at the direction and in the presence of the practitioner.

"Advertisement" means all representations disseminated in any manner or by any means, other than by labeling, for the purpose of inducing, or which are likely to induce, directly or indirectly, the purchase of drugs or devices.

"Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. It does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman.

"Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone.

"Animal" means any nonhuman animate being endowed with the power of voluntary action.

"Automated drug dispensing system" means a mechanical or electronic system that performs operations or activities, other than compounding or administration, relating to pharmacy services, including the storage, dispensing, or distribution of drugs and the collection, control, and maintenance of all transaction information, to provide security and accountability for such drugs.

"Biological product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

"Biosimilar" means a biological product that is highly similar to a specific reference biological product, notwithstanding minor differences in clinically inactive compounds, such that there are no clinically meaningful differences between the reference biological product and the biological product that has been licensed as a biosimilar pursuant to 42 U.S.C. § 262(k) in terms of safety, purity, and potency of the product.

"Board" means the Board of Pharmacy.

"Bulk drug substance" means any substance that is represented for use, and that, when used in the compounding, manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished dosage form of the drug; however, "bulk drug substance" shall not include intermediates that are used in the synthesis of such substances.

"Change of ownership" of an existing entity permitted, registered, or licensed by the Board means (i) the sale or transfer of all or substantially all of the assets of the entity or of any corporation that owns or controls the entity; (ii) the creation of a partnership by a sole proprietor, the dissolution of a partnership, or change in partnership composition; (iii) the acquisition or disposal of 50 percent or more of the outstanding shares of voting stock of a corporation owning the entity or of the parent corporation of a wholly owned subsidiary owning the entity, except that this shall not apply to any corporation the

306 voting stock of which is actively traded on any securities exchange or in any over-the-counter market;  
307 (iv) the merger of a corporation owning the entity or of the parent corporation of a wholly-owned  
308 subsidiary owning the entity with another business or corporation; or (v) the expiration or forfeiture of a  
309 corporation's charter.

310 "Co-licensed partner" means a person who, with at least one other person, has the right to engage in  
311 the manufacturing or marketing of a prescription drug, consistent with state and federal law.

312 "Compounding" means the combining of two or more ingredients to fabricate such ingredients into a  
313 single preparation and includes the mixing, assembling, packaging, or labeling of a drug or device (i) by  
314 a pharmacist, or within a permitted pharmacy, pursuant to a valid prescription issued for a medicinal or  
315 therapeutic purpose in the context of a bona fide practitioner-patient-pharmacist relationship, or in  
316 expectation of receiving a valid prescription based on observed historical patterns of prescribing and  
317 dispensing; (ii) by a practitioner of medicine, osteopathy, podiatry, dentistry, or veterinary medicine as  
318 an incident to his administering or dispensing, if authorized to dispense, a controlled substance in the  
319 course of his professional practice; or (iii) for the purpose of, or as incident to, research, teaching, or  
320 chemical analysis and not for sale or for dispensing. The mixing, diluting, or reconstituting of a  
321 manufacturer's product drugs for the purpose of administration to a patient, when performed by a  
322 practitioner of medicine or osteopathy licensed under Chapter 29 (§ 54.1-2900 et seq.), a person  
323 supervised by such practitioner pursuant to subdivision A 6 or 19 of § 54.1-2901, or a person supervised  
324 by such practitioner or a licensed nurse practitioner or physician assistant pursuant to subdivision A 4 of  
325 § 54.1-2901 shall not be considered compounding.

326 "Controlled substance" means a drug, substance, or immediate precursor in Schedules I through VI of  
327 this chapter. The term shall not include distilled spirits, wine, malt beverages, or tobacco as those terms  
328 are defined or used in Title 3.2 or Title 4.1. The term "controlled substance" includes a controlled  
329 substance analog that has been placed into Schedule I or II by the Board pursuant to the regulatory  
330 authority in subsection D of § 54.1-3443.

331 "Controlled substance analog" means a substance the chemical structure of which is substantially  
332 similar to the chemical structure of a controlled substance in Schedule I or II and either (i) which has a  
333 stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar  
334 to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a  
335 controlled substance in Schedule I or II or (ii) with respect to a particular person, which such person  
336 represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous  
337 system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect  
338 on the central nervous system of a controlled substance in Schedule I or II. "Controlled substance  
339 analog" does not include (a) any substance for which there is an approved new drug application as  
340 defined under § 505 of the federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355) or that is generally  
341 recognized as safe and effective pursuant to §§ 501, 502, and 503 of the federal Food, Drug, and  
342 Cosmetic Act (21 U.S.C. §§ 351, 352, and 353) and 21 C.F.R. Part 330; (b) with respect to a particular  
343 person, any substance for which an exemption is in effect for investigational use for that person under  
344 § 505 of the federal Food, Drug, and Cosmetic Act to the extent that the conduct with respect to that  
345 substance is pursuant to such exemption; or (c) any substance to the extent not intended for human  
346 consumption before such an exemption takes effect with respect to that substance.

347 "DEA" means the Drug Enforcement Administration, U.S. Department of Justice, or its successor  
348 agency.

349 "Deliver" or "delivery" means the actual, constructive, or attempted transfer of any item regulated by  
350 this chapter, whether or not there exists an agency relationship, including delivery of a Schedule VI  
351 prescription device to an ultimate user or consumer on behalf of a medical equipment supplier by a  
352 manufacturer, nonresident manufacturer, wholesale distributor, nonresident wholesale distributor,  
353 warehouse, nonresident warehouse, third-party logistics provider, or nonresident third-party logistics  
354 provider at the direction of a medical equipment supplier in accordance with § 54.1-3415.1.

355 "Device" means instruments, apparatus, and contrivances, including their components, parts, and  
356 accessories, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in  
357 man or animals or to affect the structure or any function of the body of man or animals.

358 "Dialysis care technician" or "dialysis patient care technician" means an individual who is certified  
359 by an organization approved by the Board of Health Professions pursuant to Chapter 27.01  
360 (§ 54.1-2729.1 et seq.) and who, under the supervision of a licensed physician, nurse practitioner,  
361 physician assistant, or a registered nurse, assists in the care of patients undergoing renal dialysis  
362 treatments in a Medicare-certified renal dialysis facility.

363 "Dialysis solution" means either the commercially available, unopened, sterile solutions whose  
364 purpose is to be instilled into the peritoneal cavity during the medical procedure known as peritoneal  
365 dialysis, or commercially available solutions whose purpose is to be used in the performance of  
366 hemodialysis not to include any solutions administered to the patient intravenously.

367 "Dispense" means to deliver a drug to an ultimate user or research subject by or pursuant to the

lawful order of a practitioner, including the prescribing and administering, packaging, labeling, or compounding necessary to prepare the substance for that delivery. However, dispensing shall not include the transportation of drugs mixed, diluted, or reconstituted in accordance with this chapter to other sites operated by such practitioner or that practitioner's medical practice for the purpose of administration of such drugs to patients of the practitioner or that practitioner's medical practice at such other sites. For practitioners of medicine or osteopathy, "dispense" shall only include the provision of drugs by a practitioner to patients to take with them away from the practitioner's place of practice.

"Dispenser" means a practitioner who dispenses.

"Distribute" means to deliver other than by administering or dispensing a controlled substance.

"Distributor" means a person who distributes.

"Drug" means (i) articles or substances recognized in the official United States Pharmacopoeia National Formulary or official Homeopathic Pharmacopoeia of the United States, or any supplement to any of them; (ii) articles or substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or animals; (iii) articles or substances, other than food, intended to affect the structure or any function of the body of man or animals; (iv) articles or substances intended for use as a component of any article specified in clause (i), (ii), or (iii); or (v) a biological product. "Drug" does not include devices or their components, parts, or accessories.

"Drug product" means a specific drug in dosage form from a known source of manufacture, whether by brand or therapeutically equivalent drug product name.

"Electronic transmission prescription" means any prescription, other than an oral or written prescription or a prescription transmitted by facsimile machine, that is electronically transmitted directly to a pharmacy without interception or intervention from a third party from a practitioner authorized to prescribe or from one pharmacy to another pharmacy.

"Facsimile (FAX) prescription" means a written prescription or order that is transmitted by an electronic device over telephone lines that sends the exact image to the receiving pharmacy in hard copy form.

"FDA" means the U.S. Food and Drug Administration.

"Hashish oil" means any oily extract containing one or more cannabinoids, but shall not include any such extract with a tetrahydrocannabinol content of less than 12 percent by weight.

"Immediate precursor" means a substance which the Board of Pharmacy has found to be and by regulation designates as being the principal compound commonly used or produced primarily for use, and which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.

"Interchangeable" means a biosimilar that meets safety standards for determining interchangeability pursuant to 42 U.S.C. § 262(k)(4).

"Label" means a display of written, printed, or graphic matter upon the immediate container of any article. A requirement made by or under authority of this chapter that any word, statement, or other information appear on the label shall not be considered to be complied with unless such word, statement, or other information also appears on the outside container or wrapper, if any, of the retail package of such article or is easily legible through the outside container or wrapper.

"Labeling" means all labels and other written, printed, or graphic matter on an article or any of its containers or wrappers, or accompanying such article.

"Manufacture" means the production, preparation, propagation, conversion, or processing of any item regulated by this chapter, either directly or indirectly by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its container. This term does not include compounding.

"Manufacturer" means every person who manufactures, a manufacturer's co-licensed partner, or a repackager.

"Marijuana" means any part of a plant of the genus *Cannabis* whether growing or not, its seeds, or its resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, or its resin. Marijuana shall not include any oily extract containing one or more cannabinoids unless such extract contains less than 12 percent of tetrahydrocannabinol by weight, nor shall marijuana include the mature stalks of such plant, fiber produced from such stalk, or oil or cake made from the seeds of such plant, unless such stalks, fiber, oil, or cake is combined with other parts of plants of the genus *Cannabis*. Marijuana shall not include (i) industrial hemp, as defined in § 3.2-4112, that is possessed by a person registered pursuant to subsection A of § 3.2-4115 or his agent, or (ii) a hemp product, as defined in § 3.2-4112, containing a tetrahydrocannabinol concentration of no greater than 0.3 percent that is derived from industrial hemp, as defined in § 3.2-4112, that is grown, dealt, or processed in compliance with state or federal law.

"Medical equipment supplier" means any person, as defined in § 1-230, engaged in the delivery to

the ultimate consumer, pursuant to the lawful order of a practitioner, of hypodermic syringes and needles, medicinal oxygen, Schedule VI controlled devices, those Schedule VI controlled substances with no medicinal properties that are used for the operation and cleaning of medical equipment, solutions for peritoneal dialysis, and sterile water or saline for irrigation.

"Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (i) opium, opiates, and any salt, compound, derivative, or preparation of opium or opiates; (ii) any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in clause (i), but not including the isoquinoline alkaloids of opium; (iii) opium poppy and poppy straw; (iv) coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extraction of coca leaves which do not contain cocaine or ecgonine.

"New drug" means (i) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling, except that such a drug not so recognized shall not be deemed to be a "new drug" if at any time prior to the enactment of this chapter it was subject to the Food and Drugs Act of June 30, 1906, as amended, and if at such time its labeling contained the same representations concerning the conditions of its use, or (ii) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized, but which has not, otherwise than in such investigations, been used to a material extent or for a material time under such conditions.

"Nuclear medicine technologist" means an individual who holds a current certification with the American Registry of Radiological Technologists or the Nuclear Medicine Technology Certification Board.

"Official compendium" means the official United States Pharmacopoeia National Formulary, official Homeopathic Pharmacopoeia of the United States, or any supplement to any of them.

"Official written order" means an order written on a form provided for that purpose by the U.S. Drug Enforcement Administration, under any laws of the United States making provision therefor, if such order forms are authorized and required by federal law, and if no such order form is provided then on an official form provided for that purpose by the Board of Pharmacy.

"Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability. It does not include, unless specifically designated as controlled under Article 4 (§ 54.1-3437 et seq.), the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does include its racemic and levorotatory forms.

"Opium poppy" means the plant of the species *Papaver somniferum* L., except the seeds thereof.

"Original package" means the unbroken container or wrapping in which any drug or medicine is enclosed together with label and labeling, put up by or for the manufacturer, wholesaler, or distributor for use in the delivery or display of such article.

"Outsourcing facility" means a facility that is engaged in the compounding of sterile drugs and is currently registered as an outsourcing facility with the U.S. Secretary of Health and Human Services and that complies with all applicable requirements of federal and state law, including the Federal Food, Drug, and Cosmetic Act.

"Person" means both the plural and singular, as the case demands, and includes an individual, partnership, corporation, association, governmental agency, trust, or other institution or entity.

"Pharmacist-in-charge" means the person who, being licensed as a pharmacist, signs the application for a pharmacy permit and assumes full legal responsibility for the operation of the relevant pharmacy in a manner complying with the laws and regulations for the practice of pharmacy and the sale and dispensing of controlled substances; the "pharmacist-in-charge" shall personally supervise the pharmacy and the pharmacy's personnel as required by § 54.1-3432.

"Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

"Practitioner" means a physician, dentist, licensed nurse practitioner pursuant to § 54.1-2957.01, licensed physician assistant pursuant to § 54.1-2952.1, pharmacist pursuant to § 54.1-3300, TPA-certified optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32, veterinarian, scientific investigator, or other person licensed, registered, or otherwise permitted to distribute, dispense, prescribe and administer, or conduct research with respect to a controlled substance in the course of professional practice or research in the Commonwealth.



"Prescriber" means a practitioner who is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue a prescription.

"Prescription" means an order for drugs or medical supplies, written or signed or transmitted by word of mouth, telephone, telegraph, or other means of communication to a pharmacist by a duly licensed physician, dentist, veterinarian, or other practitioner authorized by law to prescribe and administer such drugs or medical supplies.

"Prescription drug" means any drug required by federal law or regulation to be dispensed only pursuant to a prescription, including finished dosage forms and active ingredients subject to § 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353(b)).

"Production" or "produce" includes the manufacture, planting, cultivation, growing, or harvesting of a controlled substance or marijuana.

"Proprietary medicine" means a completely compounded nonprescription drug in its unbroken, original package which does not contain any controlled substance or marijuana as defined in this chapter and is not in itself poisonous, and which is sold, offered, promoted, or advertised directly to the general public by or under the authority of the manufacturer or primary distributor, under a trademark, trade name, or other trade symbol privately owned, and the labeling of which conforms to the requirements of this chapter and applicable federal law. However, this definition shall not include a drug that is only advertised or promoted professionally to licensed practitioners, a narcotic or drug containing a narcotic, a drug that may be dispensed only upon prescription or the label of which bears substantially the statement "Warning — may be habit-forming," or a drug intended for injection.

"Radiopharmaceutical" means any drug that exhibits spontaneous disintegration of unstable nuclei with the emission of nuclear particles or photons and includes any non-radioactive reagent kit or radionuclide generator that is intended to be used in the preparation of any such substance, but does not include drugs such as carbon-containing compounds or potassium-containing salts that include trace quantities of naturally occurring radionuclides. The term also includes any biological product that is labeled with a radionuclide or intended solely to be labeled with a radionuclide.

"Reference biological product" means the single biological product licensed pursuant to 42 U.S.C. § 262(a) against which a biological product is evaluated in an application submitted to the U.S. Food and Drug Administration for licensure of biological products as biosimilar or interchangeable pursuant to 42 U.S.C. § 262(k).

"Sale" includes barter, exchange, or gift, or offer therefor, and each such transaction made by any person, whether as an individual, proprietor, agent, servant, or employee.

"Therapeutically equivalent drug products" means drug products that contain the same active ingredients and are identical in strength or concentration, dosage form, and route of administration and that are classified as being therapeutically equivalent by the U.S. Food and Drug Administration pursuant to the definition of "therapeutically equivalent drug products" set forth in the most recent edition of the Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as the "Orange Book."

"Third-party logistics provider" means a person that provides or coordinates warehousing of or other logistics services for a drug or device in interstate commerce on behalf of a manufacturer, wholesale distributor, or dispenser of the drug or device but does not take ownership of the product or have responsibility for directing the sale or disposition of the product.

"USP-NF" means the current edition of the United States Pharmacopeia-National Formulary.

"Warehouser" means any person, other than a wholesale distributor, manufacturer, or third-party logistics provider, engaged in the business of (i) selling or otherwise distributing prescription drugs or devices to any person who is not the ultimate user or consumer and (ii) delivering Schedule VI prescription devices to the ultimate user or consumer pursuant to § 54.1-3415.1. No person shall be subject to any state or local tax by reason of this definition.

"Wholesale distribution" means (i) distribution of prescription drugs to persons other than consumers or patients and (ii) delivery of Schedule VI prescription devices to the ultimate user or consumer pursuant to § 54.1-3415.1, subject to the exemptions set forth in the federal Drug Supply Chain Security Act.

"Wholesale distributor" means any person other than a manufacturer, a manufacturer's co-licensed partner, a third-party logistics provider, or a repackager that engages in wholesale distribution.

The words "drugs" and "devices" as used in Chapter 33 (§ 54.1-3300 et seq.) and in this chapter shall not include surgical or dental instruments, physical therapy equipment, X-ray apparatus, or glasses or lenses for the eyes.

The terms "pharmacist," "pharmacy," and "practice of pharmacy" as used in this chapter shall be defined as provided in Chapter 33 (§ 54.1-3300 et seq.) unless the context requires a different meaning.

#### **§ 54.1-3401. (Effective July 1, 2020) Definitions.**

As used in this chapter, unless the context requires a different meaning:

552 "Administer" means the direct application of a controlled substance, whether by injection, inhalation,  
553 ingestion, or any other means, to the body of a patient or research subject by (i) a practitioner or by his  
554 authorized agent and under his direction or (ii) the patient or research subject at the direction and in the  
555 presence of the practitioner.

556 "Advertisement" means all representations disseminated in any manner or by any means, other than  
557 by labeling, for the purpose of inducing, or which are likely to induce, directly or indirectly, the  
558 purchase of drugs or devices.

559 "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer,  
560 distributor, or dispenser. It does not include a common or contract carrier, public warehouseman, or  
561 employee of the carrier or warehouseman.

562 "Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related  
563 to testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone.

564 "Animal" means any nonhuman animate being endowed with the power of voluntary action.

565 "Automated drug dispensing system" means a mechanical or electronic system that performs  
566 operations or activities, other than compounding or administration, relating to pharmacy services,  
567 including the storage, dispensing, or distribution of drugs and the collection, control, and maintenance of  
568 all transaction information, to provide security and accountability for such drugs.

569 "Biological product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood  
570 component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or  
571 analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic  
572 arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human  
573 beings.

574 "Biosimilar" means a biological product that is highly similar to a specific reference biological  
575 product, notwithstanding minor differences in clinically inactive compounds, such that there are no  
576 clinically meaningful differences between the reference biological product and the biological product that  
577 has been licensed as a biosimilar pursuant to 42 U.S.C. § 262(k) in terms of safety, purity, and potency  
578 of the product.

579 "Board" means the Board of Pharmacy.

580 "Bulk drug substance" means any substance that is represented for use, and that, when used in the  
581 compounding, manufacturing, processing, or packaging of a drug, becomes an active ingredient or a  
582 finished dosage form of the drug; however, "bulk drug substance" shall not include intermediates that  
583 are used in the synthesis of such substances.

584 "Change of ownership" of an existing entity permitted, registered, or licensed by the Board means (i)  
585 the sale or transfer of all or substantially all of the assets of the entity or of any corporation that owns  
586 or controls the entity; (ii) the creation of a partnership by a sole proprietor, the dissolution of a  
587 partnership, or change in partnership composition; (iii) the acquisition or disposal of 50 percent or more  
588 of the outstanding shares of voting stock of a corporation owning the entity or of the parent corporation  
589 of a wholly owned subsidiary owning the entity, except that this shall not apply to any corporation the  
590 voting stock of which is actively traded on any securities exchange or in any over-the-counter market;  
591 (iv) the merger of a corporation owning the entity or of the parent corporation of a wholly-owned  
592 subsidiary owning the entity with another business or corporation; or (v) the expiration or forfeiture of a  
593 corporation's charter.

594 "Co-licensed partner" means a person who, with at least one other person, has the right to engage in  
595 the manufacturing or marketing of a prescription drug, consistent with state and federal law.

596 "Compounding" means the combining of two or more ingredients to fabricate such ingredients into a  
597 single preparation and includes the mixing, assembling, packaging, or labeling of a drug or device (i) by  
598 a pharmacist, or within a permitted pharmacy, pursuant to a valid prescription issued for a medicinal or  
599 therapeutic purpose in the context of a bona fide practitioner-patient-pharmacist relationship, or in  
600 expectation of receiving a valid prescription based on observed historical patterns of prescribing and  
601 dispensing; (ii) by a practitioner of medicine, osteopathy, podiatry, dentistry, or veterinary medicine as  
602 an incident to his administering or dispensing, if authorized to dispense, a controlled substance in the  
603 course of his professional practice; or (iii) for the purpose of, or as incident to, research, teaching, or  
604 chemical analysis and not for sale or for dispensing. The mixing, diluting, or reconstituting of a  
605 manufacturer's product drugs for the purpose of administration to a patient, when performed by a  
606 practitioner of medicine or osteopathy licensed under Chapter 29 (§ 54.1-2900 et seq.), a person  
607 supervised by such practitioner pursuant to subdivision A 6 or 19 of § 54.1-2901, or a person supervised  
608 by such practitioner or a licensed nurse practitioner or physician assistant pursuant to subdivision A 4 of  
609 § 54.1-2901 shall not be considered compounding.

610 "Controlled substance" means a drug, substance, or immediate precursor in Schedules I through VI of  
611 this chapter. The term shall not include distilled spirits, wine, malt beverages, or tobacco as those terms  
612 are defined or used in Title 3.2 or Title 4.1. The term "controlled substance" includes a controlled  
613 substance analog that has been placed into Schedule I or II by the Board pursuant to the regulatory

authority in subsection D of § 54.1-3443.

"Controlled substance analog" means a substance the chemical structure of which is substantially similar to the chemical structure of a controlled substance in Schedule I or II and either (i) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in Schedule I or II or (ii) with respect to a particular person, which such person represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in Schedule I or II. "Controlled substance analog" does not include (a) any substance for which there is an approved new drug application as defined under § 505 of the federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355) or that is generally recognized as safe and effective pursuant to §§ 501, 502, and 503 of the federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 351, 352, and 353) and 21 C.F.R. Part 330; (b) with respect to a particular person, any substance for which an exemption is in effect for investigational use for that person under § 505 of the federal Food, Drug, and Cosmetic Act to the extent that the conduct with respect to that substance is pursuant to such exemption; or (c) any substance to the extent not intended for human consumption before such an exemption takes effect with respect to that substance.

"DEA" means the Drug Enforcement Administration, U.S. Department of Justice, or its successor agency.

"Deliver" or "delivery" means the actual, constructive, or attempted transfer of any item regulated by this chapter, whether or not there exists an agency relationship, including delivery of a Schedule VI prescription device to an ultimate user or consumer on behalf of a medical equipment supplier by a manufacturer, nonresident manufacturer, wholesale distributor, nonresident wholesale distributor, warehouse, nonresident warehouse, third-party logistics provider, or nonresident third-party logistics provider at the direction of a medical equipment supplier in accordance with § 54.1-3415.1.

"Device" means instruments, apparatus, and contrivances, including their components, parts, and accessories, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or animals or to affect the structure or any function of the body of man or animals.

"Dialysis care technician" or "dialysis patient care technician" means an individual who is certified by an organization approved by the Board of Health Professions pursuant to Chapter 27.01 (§ 54.1-2729.1 et seq.) and who, under the supervision of a licensed physician, nurse practitioner, physician assistant, or a registered nurse, assists in the care of patients undergoing renal dialysis treatments in a Medicare-certified renal dialysis facility.

"Dialysis solution" means either the commercially available, unopened, sterile solutions whose purpose is to be instilled into the peritoneal cavity during the medical procedure known as peritoneal dialysis, or commercially available solutions whose purpose is to be used in the performance of hemodialysis not to include any solutions administered to the patient intravenously.

"Dispense" means to deliver a drug to an ultimate user or research subject by or pursuant to the lawful order of a practitioner, including the prescribing and administering, packaging, labeling, or compounding necessary to prepare the substance for that delivery. However, dispensing shall not include the transportation of drugs mixed, diluted, or reconstituted in accordance with this chapter to other sites operated by such practitioner or that practitioner's medical practice for the purpose of administration of such drugs to patients of the practitioner or that practitioner's medical practice at such other sites. For practitioners of medicine or osteopathy, "dispense" shall only include the provision of drugs by a practitioner to patients to take with them away from the practitioner's place of practice.

"Dispenser" means a practitioner who dispenses.

"Distribute" means to deliver other than by administering or dispensing a controlled substance.

"Distributor" means a person who distributes.

"Drug" means (i) articles or substances recognized in the official United States Pharmacopoeia National Formulary or official Homeopathic Pharmacopoeia of the United States, or any supplement to any of them; (ii) articles or substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or animals; (iii) articles or substances, other than food, intended to affect the structure or any function of the body of man or animals; (iv) articles or substances intended for use as a component of any article specified in clause (i), (ii), or (iii); or (v) a biological product. "Drug" does not include devices or their components, parts, or accessories.

"Drug product" means a specific drug in dosage form from a known source of manufacture, whether by brand or therapeutically equivalent drug product name.

"Electronic prescription" means a written prescription that is generated on an electronic application and is transmitted to a pharmacy as an electronic data file; Schedule II through V prescriptions shall be transmitted in accordance with 21 C.F.R. Part 1300.

"Facsimile (FAX) prescription" means a written prescription or order that is transmitted by an

675 electronic device over telephone lines that sends the exact image to the receiving pharmacy in hard copy  
676 form.

677 "FDA" means the U.S. Food and Drug Administration.

678 "Hashish oil" means any oily extract containing one or more cannabinoids, but shall not include any  
679 such extract with a tetrahydrocannabinol content of less than 12 percent by weight.

680 "Immediate precursor" means a substance which the Board of Pharmacy has found to be and by  
681 regulation designates as being the principal compound commonly used or produced primarily for use,  
682 and which is an immediate chemical intermediary used or likely to be used in the manufacture of a  
683 controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.

684 "Interchangeable" means a biosimilar that meets safety standards for determining interchangeability  
685 pursuant to 42 U.S.C. § 262(k)(4).

686 "Label" means a display of written, printed, or graphic matter upon the immediate container of any  
687 article. A requirement made by or under authority of this chapter that any word, statement, or other  
688 information appear on the label shall not be considered to be complied with unless such word,  
689 statement, or other information also appears on the outside container or wrapper, if any, of the retail  
690 package of such article or is easily legible through the outside container or wrapper.

691 "Labeling" means all labels and other written, printed, or graphic matter on an article or any of its  
692 containers or wrappers, or accompanying such article.

693 "Manufacture" means the production, preparation, propagation, conversion, or processing of any item  
694 regulated by this chapter, either directly or indirectly by extraction from substances of natural origin, or  
695 independently by means of chemical synthesis, or by a combination of extraction and chemical  
696 synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its  
697 container. This term does not include compounding.

698 "Manufacturer" means every person who manufactures, a manufacturer's co-licensed partner, or a  
699 repackager.

700 "Marijuana" means any part of a plant of the genus *Cannabis* whether growing or not, its seeds, or  
701 its resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its  
702 seeds, or its resin. Marijuana shall not include any oily extract containing one or more cannabinoids  
703 unless such extract contains less than 12 percent of tetrahydrocannabinol by weight, nor shall marijuana  
704 include the mature stalks of such plant, fiber produced from such stalk, or oil or cake made from the  
705 seeds of such plant, unless such stalks, fiber, oil, or cake is combined with other parts of plants of the  
706 genus *Cannabis*. Marijuana shall not include (i) industrial hemp, as defined in § 3.2-4112, that is  
707 possessed by a person registered pursuant to subsection A of § 3.2-4115 or his agent, or (ii) *a hemp*  
708 *product, as defined in § 3.2-4112, containing a tetrahydrocannabinol concentration of no greater than*  
709 *0.3 percent that is derived from industrial hemp, as defined in § 3.2-4112, that is grown, dealt, or*  
710 *processed in compliance with state or federal law.*

711 "Medical equipment supplier" means any person, as defined in § 1-230, engaged in the delivery to  
712 the ultimate consumer, pursuant to the lawful order of a practitioner, of hypodermic syringes and  
713 needles, medicinal oxygen, Schedule VI controlled devices, those Schedule VI controlled substances with  
714 no medicinal properties that are used for the operation and cleaning of medical equipment, solutions for  
715 peritoneal dialysis, and sterile water or saline for irrigation.

716 "Narcotic drug" means any of the following, whether produced directly or indirectly by extraction  
717 from substances of vegetable origin, or independently by means of chemical synthesis, or by a  
718 combination of extraction and chemical synthesis: (i) opium, opiates, and any salt, compound, derivative,  
719 or preparation of opium or opiates; (ii) any salt, compound, isomer, derivative, or preparation thereof  
720 which is chemically equivalent or identical with any of the substances referred to in clause (i), but not  
721 including the isoquinoline alkaloids of opium; (iii) opium poppy and poppy straw; (iv) coca leaves and  
722 any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, isomer,  
723 derivative, or preparation thereof which is chemically equivalent or identical with any of these  
724 substances, but not including decocainized coca leaves or extraction of coca leaves which do not contain  
725 cocaine or ecgonine.

726 "New drug" means (i) any drug, except a new animal drug or an animal feed bearing or containing a  
727 new animal drug, the composition of which is such that such drug is not generally recognized, among  
728 experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs,  
729 as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling,  
730 except that such a drug not so recognized shall not be deemed to be a "new drug" if at any time prior  
731 to the enactment of this chapter it was subject to the Food and Drugs Act of June 30, 1906, as  
732 amended, and if at such time its labeling contained the same representations concerning the conditions  
733 of its use, or (ii) any drug, except a new animal drug or an animal feed bearing or containing a new  
734 animal drug, the composition of which is such that such drug, as a result of investigations to determine  
735 its safety and effectiveness for use under such conditions, has become so recognized, but which has not,  
736 otherwise than in such investigations, been used to a material extent or for a material time under such

conditions.

"Nuclear medicine technologist" means an individual who holds a current certification with the American Registry of Radiological Technologists or the Nuclear Medicine Technology Certification Board.

"Official compendium" means the official United States Pharmacopoeia National Formulary, official Homeopathic Pharmacopoeia of the United States, or any supplement to any of them.

"Official written order" means an order written on a form provided for that purpose by the U.S. Drug Enforcement Administration, under any laws of the United States making provision therefor, if such order forms are authorized and required by federal law, and if no such order form is provided then on an official form provided for that purpose by the Board of Pharmacy.

"Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability. It does not include, unless specifically designated as controlled under Article 4 (§ 54.1-3437 et seq.), the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does include its racemic and levorotatory forms.

"Opium poppy" means the plant of the species *Papaver somniferum* L., except the seeds thereof.

"Original package" means the unbroken container or wrapping in which any drug or medicine is enclosed together with label and labeling, put up by or for the manufacturer, wholesaler, or distributor for use in the delivery or display of such article.

"Outsourcing facility" means a facility that is engaged in the compounding of sterile drugs and is currently registered as an outsourcing facility with the U.S. Secretary of Health and Human Services and that complies with all applicable requirements of federal and state law, including the Federal Food, Drug, and Cosmetic Act.

"Person" means both the plural and singular, as the case demands, and includes an individual, partnership, corporation, association, governmental agency, trust, or other institution or entity.

"Pharmacist-in-charge" means the person who, being licensed as a pharmacist, signs the application for a pharmacy permit and assumes full legal responsibility for the operation of the relevant pharmacy in a manner complying with the laws and regulations for the practice of pharmacy and the sale and dispensing of controlled substances; the "pharmacist-in-charge" shall personally supervise the pharmacy and the pharmacy's personnel as required by § 54.1-3432.

"Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

"Practitioner" means a physician, dentist, licensed nurse practitioner pursuant to § 54.1-2957.01, licensed physician assistant pursuant to § 54.1-2952.1, pharmacist pursuant to § 54.1-3300, TPA-certified optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32, veterinarian, scientific investigator, or other person licensed, registered, or otherwise permitted to distribute, dispense, prescribe and administer, or conduct research with respect to a controlled substance in the course of professional practice or research in the Commonwealth.

"Prescriber" means a practitioner who is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue a prescription.

"Prescription" means an order for drugs or medical supplies, written or signed or transmitted by word of mouth, telephone, telegraph, or other means of communication to a pharmacist by a duly licensed physician, dentist, veterinarian, or other practitioner authorized by law to prescribe and administer such drugs or medical supplies.

"Prescription drug" means any drug required by federal law or regulation to be dispensed only pursuant to a prescription, including finished dosage forms and active ingredients subject to § 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353(b)).

"Production" or "produce" includes the manufacture, planting, cultivation, growing, or harvesting of a controlled substance or marijuana.

"Proprietary medicine" means a completely compounded nonprescription drug in its unbroken, original package which does not contain any controlled substance or marijuana as defined in this chapter and is not in itself poisonous, and which is sold, offered, promoted, or advertised directly to the general public by or under the authority of the manufacturer or primary distributor, under a trademark, trade name, or other trade symbol privately owned, and the labeling of which conforms to the requirements of this chapter and applicable federal law. However, this definition shall not include a drug that is only advertised or promoted professionally to licensed practitioners, a narcotic or drug containing a narcotic, a drug that may be dispensed only upon prescription or the label of which bears substantially the statement "Warning — may be habit-forming," or a drug intended for injection.

"Radiopharmaceutical" means any drug that exhibits spontaneous disintegration of unstable nuclei with the emission of nuclear particles or photons and includes any non-radioactive reagent kit or radionuclide generator that is intended to be used in the preparation of any such substance, but does not include drugs such as carbon-containing compounds or potassium-containing salts that include trace

quantities of naturally occurring radionuclides. The term also includes any biological product that is labeled with a radionuclide or intended solely to be labeled with a radionuclide.

"Reference biological product" means the single biological product licensed pursuant to 42 U.S.C. § 262(a) against which a biological product is evaluated in an application submitted to the U.S. Food and Drug Administration for licensure of biological products as biosimilar or interchangeable pursuant to 42 U.S.C. § 262(k).

"Sale" includes barter, exchange, or gift, or offer therefor, and each such transaction made by any person, whether as an individual, proprietor, agent, servant, or employee.

"Therapeutically equivalent drug products" means drug products that contain the same active ingredients and are identical in strength or concentration, dosage form, and route of administration and that are classified as being therapeutically equivalent by the U.S. Food and Drug Administration pursuant to the definition of "therapeutically equivalent drug products" set forth in the most recent edition of the Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as the "Orange Book."

"Third-party logistics provider" means a person that provides or coordinates warehousing of or other logistics services for a drug or device in interstate commerce on behalf of a manufacturer, wholesale distributor, or dispenser of the drug or device but does not take ownership of the product or have responsibility for directing the sale or disposition of the product.

"USP-NF" means the current edition of the United States Pharmacopeia-National Formulary.

"Warehouser" means any person, other than a wholesale distributor, manufacturer, or third-party logistics provider, engaged in the business of (i) selling or otherwise distributing prescription drugs or devices to any person who is not the ultimate user or consumer and (ii) delivering Schedule VI prescription devices to the ultimate user or consumer pursuant to § 54.1-3415.1. No person shall be subject to any state or local tax by reason of this definition.

"Wholesale distribution" means (i) distribution of prescription drugs to persons other than consumers or patients and (ii) delivery of Schedule VI prescription devices to the ultimate user or consumer pursuant to § 54.1-3415.1, subject to the exemptions set forth in the federal Drug Supply Chain Security Act.

"Wholesale distributor" means any person other than a manufacturer, a manufacturer's co-licensed partner, a third-party logistics provider, or a repackager that engages in wholesale distribution.

The words "drugs" and "devices" as used in Chapter 33 (§ 54.1-3300 et seq.) and in this chapter shall not include surgical or dental instruments, physical therapy equipment, X-ray apparatus, or glasses or lenses for the eyes.

The terms "pharmacist," "pharmacy," and "practice of pharmacy" as used in this chapter shall be defined as provided in Chapter 33 (§ 54.1-3300 et seq.) unless the context requires a different meaning.

### **§ 54.1-3408.3. Certification for use of cannabidiol oil or THC-A oil for treatment.**

A. As used in this section:

"Cannabidiol oil" means a processed Cannabis plant extract that contains at least 15 percent cannabidiol but no more than five percent tetrahydrocannabinol, or a dilution of the resin of the Cannabis plant that contains at least five milligrams of cannabidiol per milliliter but not more than five percent tetrahydrocannabinol. *"Cannabidiol oil" does not include industrial hemp, as defined in § 3.2-4112, that is grown, dealt, or processed in compliance with state or federal law.*

"Practitioner" means a practitioner of medicine or osteopathy licensed by the Board of Medicine.

"THC-A oil" means a processed Cannabis plant extract that contains at least 15 percent tetrahydrocannabinol acid but not more than five percent tetrahydrocannabinol, or a dilution of the resin of the Cannabis plant that contains at least five milligrams of tetrahydrocannabinol acid per milliliter but not more than five percent tetrahydrocannabinol.

B. A practitioner in the course of his professional practice may issue a written certification for the use of cannabidiol oil or THC-A oil for treatment or to alleviate the symptoms of any diagnosed condition or disease determined by the practitioner to benefit from such use.

C. The written certification shall be on a form provided by the Office of the Executive Secretary of the Supreme Court developed in consultation with the Board of Medicine. Such written certification shall contain the name, address, and telephone number of the practitioner, the name and address of the patient issued the written certification, the date on which the written certification was made, and the signature of the practitioner. Such written certification issued pursuant to subsection B shall expire no later than one year after its issuance unless the practitioner provides in such written certification an earlier expiration.

D. No practitioner shall be prosecuted under § 18.2-248 or 18.2-248.1 for dispensing or distributing cannabidiol oil or THC-A oil for the treatment or to alleviate the symptoms of a patient's diagnosed condition or disease pursuant to a written certification issued pursuant to subsection B. Nothing in this section shall preclude the Board of Medicine from sanctioning a practitioner for failing to properly evaluate or treat a patient's medical condition or otherwise violating the applicable standard of care for

evaluating or treating medical conditions.

E. A practitioner who issues a written certification to a patient pursuant to this section shall register with the Board. The Board shall, in consultation with the Board of Medicine, set a limit on the number of patients to whom a practitioner may issue a written certification.

F. A patient who has been issued a written certification shall register with the Board or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, a patient's parent or legal guardian shall register and shall register such patient with the Board.

G. The Board shall promulgate regulations to implement the registration process. Such regulations shall include (i) a mechanism for sufficiently identifying the practitioner issuing the written certification, the patient being treated by the practitioner, and, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, the patient's parent or legal guardian; (ii) a process for ensuring that any changes in the information are reported in an appropriate timeframe; and (iii) a prohibition for the patient to be issued a written certification by more than one practitioner during any given time period.

H. Information obtained under the registration process shall be confidential and shall not be subject to the disclosure provisions of the Virginia Freedom of Information Act (§ 2.2-3700 et seq.). However, reasonable access to registry information shall be provided to (i) the Chairmen of the House and Senate Committees for Courts of Justice, (ii) state and federal agencies or local law enforcement for the purpose of investigating or prosecuting a specific individual for a specific violation of law, (iii) licensed physicians or pharmacists for the purpose of providing patient care and drug therapy management and monitoring of drugs obtained by a registered patient, (iv) a pharmaceutical processor involved in the treatment of a registered patient, or (v) a registered patient or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, the patient's parent or legal guardian, but only with respect to information related to such registered patient.

#### § 54.1-3446. Schedule I.

The controlled substances listed in this section are included in Schedule I:

1. Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (other name: PEPAP);

1-methyl-4-phenyl-4-propionoxypiperidine (other name: MPPP);

2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide (other name: Methoxyacetyl fentanyl);

3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (other name: U-47700);

3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (other name: AH-7921);

Acetyl fentanyl (other name: desmethyl fentanyl);

Acetylmethadol;

Allylprodine;

Alphacetylmethadol (except levo-alpha-acetylmethadol, also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);

Alphameprodine;

Alphamethadol;

Benzethidine;

Betacetylmethadol;

Betameprodine;

Betamethadol;

Betaprodine;

Clonitazene;

Dextromoramide;

Diampromide;

Diethylthiambutene;

Difenoxin;

Dimenoxadol;

Dimepheptanol;

Dimethylthiambutene;

Dioxaphetylbutyrate;

Dipipanone;

Ethylmethylthiambutene;

Etonitazene;

Etoxidine;

Furethidine;

Hydroxypethidine;

- 921 Ketobemidone;  
922 Levomoramide;  
923 Levophenacetylmorphan;  
924 Morpheridine;  
925 N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (other name: Cyclopropyl fentanyl);  
926 N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide (other name: Tetrahydrofuranyl  
927 fentanyl);  
928 N-[1-[1-methyl-2-(2-thienyl)ethyl]-4-piperidyl]-N-phenylpropanamide (other name:  
929 alpha-methylthiofentanyl);  
930 N-[1-(1-methyl-2-phenylethyl)-4-piperidyl]-N-phenylacetamide (other name:  
931 acetyl-alpha-methylfentanyl);  
932 N-{1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyll}-N-phenylpropanamide (other name:  
933 beta-hydroxythiofentanyl);  
934 N-[1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl]-N-phenylpropanamide (other name:  
935 beta-hydroxyfentanyl);  
936 N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide (other names:  
937 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine, alpha-methylfentanyl);  
938 N-(2-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyll]-propanamide (other names: 2-fluorofentanyl,  
939 ortho-fluorofentanyl);  
940 N-(3-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyll]-propanamide (other name: 3-fluorofentanyl);  
941 N-[3-methyl-1-(2-hydroxy-2-phenylethyl)-4-piperidyl]-N-phenylpropanamide (other name:  
942 beta-hydroxy-3-methylfentanyl);  
943 N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide (other name: 3-methylfentanyl);  
944 N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyll]-N-phenylpropanamide (other name:  
945 3-methylthiofentanyl);  
946 N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyll]-propanamide (other name:  
947 para-fluoroisobutryl fentanyl);  
948 N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyll]-butanamide (other name:  
949 para-fluorobutryl fentanyl);  
950 N-(4-fluorophenyl)-N-1-(2-phenylethyl)-4-piperidinyll]-propanamide (other name: para-fluorofentanyl);  
951 Noracymethadol;  
952 Norlevorphanol;  
953 Normethadone;  
954 Norpipanone;  
955 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyll]-2-furancarboxamide (other name: Furanyl fentanyl);  
956 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyll]-2-propenamide (other name: Acryl fentanyl);  
957 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyll]-butanamide (other name: butyryl fentanyl);  
958 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyll]-pentanamide (other name: Pentanoyl fentanyl);  
959 N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyll]-propanamide (other name: thiofentanyl);  
960 Phenadoxone;  
961 Phenampromide;  
962 Phenomorphan;  
963 Phenoperidine;  
964 Piritramide;  
965 Proheptazine;  
966 Properidine;  
967 Propiram;  
968 Racemoramide;  
969 Tilidine;  
970 Trimeperidine.  
971 2. Any of the following opium derivatives, their salts, isomers and salts of isomers, unless  
972 specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible  
973 within the specific chemical designation:  
974 Acetorphine;  
975 Acetyldihydrocodeine;  
976 Benzylmorphine;  
977 Codeine methylbromide;  
978 Codeine-N-Oxide;  
979 Cyprenorphine;  
980 Desomorphine;  
981 Dihydromorphine;  
982 Drotebanol;



- 983 Etorphine;  
 984 Heroin;  
 985 Hydromorphenol;  
 986 Methyldesorphine;  
 987 Methyldihydromorphine;  
 988 Morphine methylbromide;  
 989 Morphine methylsulfonate;  
 990 Morphine-N-Oxide;  
 991 Myrophine;  
 992 Nicocodeine;  
 993 Nicomorphine;  
 994 Normorphine;  
 995 Pholcodine;  
 996 Thebacon.  
 997 3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture,  
 998 or preparation, which contains any quantity of the following hallucinogenic substances, or which  
 999 contains any of its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers,  
 1000 and salts of isomers is possible within the specific chemical designation (for purposes of this subdivision  
 1001 only, the term "isomer" includes the optical, position, and geometric isomers):  
 1002 Alpha-ethyltryptamine (some trade or other names: Monase; a-ethyl-1H-indole-3-ethanamine;  
 1003 3-2-aminobutyl] indole; a-ET; AET);  
 1004 4-Bromo-2,5-dimethoxyphenethylamine (some trade or other names:  
 1005 2-4-bromo-2,5-dimethoxyphenyl]-1-aminoethane; alpha-desmethyl DOB; 2C-B; Nexus);  
 1006 3,4-methylenedioxy amphetamine;  
 1007 5-methoxy-3,4-methylenedioxy amphetamine;  
 1008 3,4,5-trimethoxy amphetamine;  
 1009 Alpha-methyltryptamine (other name: AMT);  
 1010 Bufotenine;  
 1011 Diethyltryptamine;  
 1012 Dimethyltryptamine;  
 1013 4-methyl-2,5-dimethoxyamphetamine;  
 1014 2,5-dimethoxy-4-ethylamphetamine (DOET);  
 1015 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7);  
 1016 Ibogaine;  
 1017 5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT);  
 1018 Lysergic acid diethylamide;  
 1019 Mescaline;  
 1020 Parahexyl (some trade or other names:  
 1021 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl);  
 1022 Peyote;  
 1023 N-ethyl-3-piperidyl benzilate;  
 1024 N-methyl-3-piperidyl benzilate;  
 1025 Psilocybin;  
 1026 Psilocyn;  
 1027 Salvinorin A;  
 1028 Tetrahydrocannabinols, except as present in (i) industrial hemp, as defined in § 3.2-4112, that is  
 1029 possessed by a person registered pursuant to subsection A of § 3.2-4115 or his agent; (ii) a hemp  
 1030 product, as defined in § 3.2-4112, containing a tetrahydrocannabinol concentration of no greater than  
 1031 0.3 percent that is derived from industrial hemp, as defined in § 3.2-4112, that is grown, dealt, or  
 1032 processed in compliance with state or federal law; (iii) marijuana ~~and~~; or (iv) dronabinol in sesame oil  
 1033 and encapsulated in a soft gelatin capsule in a drug product approved by the U.S. Food and Drug  
 1034 Administration;  
 1035 Hashish oil (some trade or other names: hash oil; liquid marijuana; liquid hashish);  
 1036 2,5-dimethoxyamphetamine (some trade or other names: 2,5-dimethoxy-a-methylphenethylamine;  
 1037 2,5-DMA);  
 1038 3,4-methylenedioxymethamphetamine (MDMA), its optical, positional and geometric isomers, salts  
 1039 and salts of isomers;  
 1040 3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-alpha-methyl-3,4  
 1041 (methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA);  
 1042 N-hydroxy-3,4-methylenedioxyamphetamine (some other names:  
 1043 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA);

- 1044 4-bromo-2,5-dimethoxyamphetamine (some trade or other names:  
 1045 4-bromo-2,5-dimethoxy-a-methylphenethylamine; 4-bromo-2,5-DMA);  
 1046 4-methoxyamphetamine (some trade or other names: 4-methoxy-a-methylphenethylamine;  
 1047 paramethoxyamphetamine; PMA);  
 1048 Ethylamine analog of phencyclidine (some other names: N-ethyl-1-phenylcyclohexylamine,  
 1049 (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE);  
 1050 Pyrrolidine analog of phencyclidine (some other names: 1-(1-phenylcyclohexyl) -pyrrolidine, PCPy,  
 1051 PHP);  
 1052 Thiophene analog of phencyclidine (some other names: 1-[1-(2-thienyl) -cyclohexyl]-piperidine,  
 1053 2-thienyl analog of phencyclidine, TPCP, TCP);  
 1054 1-1-(2-thienyl)cyclohexyl]pyrrolidine (other name: TCPy);  
 1055 3,4-methylenedioxypyrovalerone (other name: MDPV);  
 1056 4-methylmethcathinone (other names: mephedrone, 4-MMC);  
 1057 3,4-methylenedioxymethcathinone (other name: methylone);  
 1058 Naphthylpyrovalerone (other name: naphyrone);  
 1059 4-fluoromethcathinone (other name: flephedrone, 4-FMC);  
 1060 4-methoxymethcathinone (other names: methedrone; bk-PMMA);  
 1061 Ethcathinone (other name: N-ethylcathinone);  
 1062 3,4-methylenedioxyethcathinone (other name: ethylone);  
 1063 Beta-keto-N-methyl-3,4-benzodioxolylbutanamine (other name: butylone);  
 1064 N,N-dimethylcathinone (other name: metamfepramone);  
 1065 Alpha-pyrrolidinopropiophenone (other name: alpha-PPP);  
 1066 4-methoxy-alpha-pyrrolidinopropiophenone (other name: MOPPP);  
 1067 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone (other name: MDPPP);  
 1068 Alpha-pyrrolidinovalerophenone (other name: alpha-PVP);  
 1069 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine (other name: MDAI);  
 1070 3-fluoromethcathinone (other name: 3-FMC);  
 1071 4-Ethyl-2,5-dimethoxyphenethylamine (other name: 2C-E);  
 1072 4-Iodo-2,5-dimethoxyphenethylamine (other name: 2C-I);  
 1073 4-Methylethcathinone (other name: 4-MEC);  
 1074 4-Ethylmethcathinone (other name: 4-EMC);  
 1075 N,N-diallyl-5-methoxytryptamine (other name: 5-MeO-DALT);  
 1076 Beta-keto-methylbenzodioxolylpentanamine (other name: Pentylone, bk-MBDP);  
 1077 Alpha-methylamino-butyrophenone (other name: Buphedrone);  
 1078 Alpha-methylamino-valerophenone (other name: Pentedrone);  
 1079 3,4-Dimethylmethcathinone (other name: 3,4-DMMC);  
 1080 4-methyl-alpha-pyrrolidinopropiophenone (other name: MPPP);  
 1081 4-Iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (other names: 25-I,  
 1082 25I-NBOMe, 2C-I-NBOMe);  
 1083 Methoxetamine (other names: MXE, 3-MeO-2-Oxo-PCE);  
 1084 4-Fluoromethamphetamine (other name: 4-FMA);  
 1085 4-Fluoroamphetamine (other name: 4-FA);  
 1086 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (other name: 2C-D);  
 1087 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (other name: 2C-C);  
 1088 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (other name: 2C-T-2);  
 1089 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (other name: 2C-T-4);  
 1090 2-(2,5-Dimethoxyphenyl)ethanamine (other name: 2C-H);  
 1091 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (other name: 2C-N);  
 1092 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (other name: 2C-P);  
 1093 (2-aminopropyl)benzofuran (other name: APB);  
 1094 (2-aminopropyl)-2,3-dihydrobenzofuran (other name: APDB);  
 1095 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (other names:  
 1096 2C-C-NBOMe, 25C-NBOMe, 25C);  
 1097 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (other names:  
 1098 2C-B-NBOMe, 25B-NBOMe, 25B);  
 1099 Acetoxymethyltryptamine (other names: AcO-Psilocin, AcO-DMT, Psilacetin);  
 1100 Benocyclidine (other names: BCP, BTCP);  
 1101 Alpha-pyrrolidinobutyrophenone (other name: alpha-PBP);  
 1102 3,4-methylenedioxy-N,N-dimethylcathinone (other names: Dimethylone, bk-MDDMA);  
 1103 4-bromomethcathinone (other name: 4-BMC);  
 1104 4-chloromethcathinone (other name: 4-CMC);  
 1105 4-Iodo-2,5-dimethoxy-N-[(2-hydroxyphenyl)methyl]-benzeneethanamine (other name: 25I-NBOH);

- 1106 Alpha-Pyrrolidinohexiophenone (other name: alpha-PHP);  
 1107 Alpha-Pyrrolidinoheptiophenone (other name: PV8);  
 1108 5-methoxy-N,N-methylisopropyltryptamine (other name: 5-MeO-MIPT);  
 1109 Beta-keto-N,N-dimethylbenzodioxolylbutanamine (other names: Dibutylone, bk-DMBDB);  
 1110 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone (other name: N-ethylpentylone);  
 1111 1-[1-(3-methoxyphenyl)cyclohexyl]piperidine (other name: 3-methoxy PCP);  
 1112 1-[1-(4-methoxyphenyl)cyclohexyl]piperidine (other name: 4-methoxy PCP);  
 1113 4-Chloroethcathinone (other name: 4-CEC);  
 1114 3-Methoxy-2-(methylamino)-1-(4-methylphenyl)-1-propanone (other name: Mexedrone);  
 1115 1-propionyl lysergic acid diethylamide (other name: 1P-LSD);  
 1116 (2-Methylaminopropyl)benzofuran (other name: MAPB);  
 1117 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-pentanone (other names: N,N-Dimethylpentylone,  
 1118 Dipentylone);  
 1119 1-(4-methoxyphenyl)-2-(pyrrolidin-1-yl)octan-1-one (other name: 4-methoxy-PV9)  
 1120 3,4-tetramethylene-alpha-pyrrolidinovalerophenone (other name: TH-PVP);  
 1121 4-allyloxy-3,5-dimethoxyphenethylamine (other name: Allylescaine);  
 1122 4-Bromo-2,5-dimethoxy-N-[(2-hydroxyphenyl)methyl]-benzeneethanamine (other name: 25B-NBOH);  
 1123 4-chloro-alpha-methylamino-valerophenone (other name: 4-chloropentedrone);  
 1124 4-chloro-alpha-Pyrrolidinovalerophenone (other name: 4-chloro-alpha-PVP);  
 1125 4-fluoro-alpha-Pyrrolidinoheptiophenone (other name: 4-fluoro-PV8);  
 1126 4-hydroxy-N,N-diisopropyltryptamine (other name: 4-OH-DIPT);  
 1127 4-methyl-alpha-ethylaminopentiophenone;  
 1128 4-methyl-alpha-Pyrrolidinohexiophenone (other name: MPHP);  
 1129 5-methoxy-N,N-dimethyltryptamine (other name: 5-MeO-DMT);  
 1130 5-methoxy-N-ethyl-N-isopropyltryptamine (other name: 5-MeO-EIPT);  
 1131 6-ethyl-6-nor-lysergic acid diethylamide (other name: ETH-LAD);  
 1132 6-allyl-6-nor-lysergic acid diethylamide (other name: AL-LAD);  
 1133 (N-methyl aminopropyl)-2,3-dihydrobenzofuran (other name: MAPDB).  
 1134 4. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture  
 1135 or preparation which contains any quantity of the following substances having a depressant effect on the  
 1136 central nervous system, including its salts, isomers and salts of isomers whenever the existence of such  
 1137 salts, isomers and salts of isomers is possible within the specific chemical designation:  
 1138 Clonazepam;  
 1139 Etizolam;  
 1140 Flubromazepam;  
 1141 Flubromazolam;  
 1142 Gamma hydroxybutyric acid (some other names include GHB; gamma hydroxybutyrate;  
 1143 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);  
 1144 Mecloqualone;  
 1145 Methaqualone.  
 1146 5. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture  
 1147 or preparation which contains any quantity of the following substances having a stimulant effect on the  
 1148 central nervous system, including its salts, isomers and salts of isomers:  
 1149 2-(3-fluorophenyl)-3-methylmorpholine (other name: 3-fluorophenmetrazine);  
 1150 Aminorex (some trade or other names; aminoxaphen; 2-amino-5-phenyl-2-oxazoline;  
 1151 4,5-dihydro-5-phenyl-2-oxazolamine);  
 1152 Cathinone (some trade or other names: 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone,  
 1153 2-aminopropiophenone, norephedrone), and any plant material from which Cathinone may be derived;  
 1154 Cis-4-methylaminorex (other name: cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);  
 1155 Ethylamphetamine;  
 1156 Ethyl phenyl(piperidin-2-yl)acetate (other name: Ethylphenidate);  
 1157 Fenethylamine;  
 1158 Methcathinone (some other names: 2-(methylamino)-propionophenone;  
 1159 alpha-(methylamino)-propionophenone; 2-(methylamino)-1-phenylpropan-1-one;  
 1160 alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;  
 1161 methylcathinone; AL-464; AL-422; AL-463 and UR 1432);  
 1162 N-Benzylpiperazine (some other names: BZP, 1-benzylpiperazine);  
 1163 N,N-dimethylamphetamine (other names: N, N-alpha-trimethyl-benzeneethanamine, N,  
 1164 N-alpha-trimethylphenethylamine).  
 1165 6. Any substance that contains one or more cannabimimetic agents or that contains their salts,  
 1166 isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is

- possible within the specific chemical designation, and any preparation, mixture, or substance containing, or mixed or infused with, any detectable amount of one or more cannabimimetic agents.
- a. "Cannabimimetic agents" includes any substance that is within any of the following structural classes:
- 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent;
  - 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent;
  - 3-(1-naphthoyl)pyrrole with substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent;
  - 1-(1-naphthylmethyl)indene with substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent;
  - 3-phenylacetylindole or 3-benzoylindole with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent;
  - 3-cyclopropoylindole with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the cyclopropyl ring to any extent;
  - 3-adamantoylindole with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the adamantyl ring to any extent;
  - N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the adamantyl ring to any extent; and
  - N-(adamantyl)-indazole-3-carboxamide with substitution at a nitrogen atom of the indazole ring, whether or not further substituted on the indazole ring to any extent, whether or not substituted on the adamantyl ring to any extent.
- b. The term "cannabimimetic agents" includes:
- 5-(1,1-Dimethylheptyl)-2-[3-hydroxycyclohexyl]-phenol (other name: CP 47,497);
  - 5-(1,1-Dimethylhexyl)-2-[3-hydroxycyclohexyl]-phenol (other name: CP 47,497 C6 homolog);
  - 5-(1,1-Dimethyloctyl)-2-[3-hydroxycyclohexyl]-phenol (other name: CP 47,497 C8 homolog);
  - 5-(1,1-Dimethylnonyl)-2-[3-hydroxycyclohexyl]-phenol (other name: CP 47,497 C9 homolog);
  - 1-pentyl-3-(1-naphthoyl)indole (other names: JWH-018, AM-678);
  - 1-butyl-3-(1-naphthoyl)indole (other name: JWH-073);
  - 1-pentyl-3-(2-methoxyphenylacetyl)indole (other name: JWH-250);
  - 1-hexyl-3-(naphthalen-1-oyl)indole (other name: JWH-019);
  - 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (other name: JWH-200);
  - (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (other name: HU-210);
  - 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (other name: JWH-081);
  - 1-pentyl-3-(4-methyl-1-naphthoyl)indole (other name: JWH-122);
  - 1-pentyl-3-(2-chlorophenylacetyl)indole (other name: JWH-203);
  - 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (other name: JWH-210);
  - 1-pentyl-3-(4-chloro-1-naphthoyl)indole (other name: JWH-398);
  - 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (other name: AM-694);
  - 1-((N-methylpiperidin-2-yl)methyl)-3-(1-naphthoyl)indole (other name: AM-1220);
  - 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (other name: AM-2201);
  - 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole (other name: AM-2233);
  - Pravadoline (4-methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (other name: WIN 48,098);
  - 1-pentyl-3-(4-methoxybenzoyl)indole (other names: RCS-4, SR-19);
  - 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (other names: RCS-8, SR-18);
  - 1-pentyl-3-(2,2,3,3-tetramethylcyclopropylmethanone)indole (other name: UR-144);
  - 1-(5-fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropylmethanone)indole (other names: XLR-11, 5-fluoro-UR-144);
  - N-adamantyl-1-fluoropentylindole-3-carboxamide (other name: STS-135);
  - N-adamantyl-1-pentylindazole-3-carboxamide (other names: AKB48, APINACA);
  - 1-pentyl-3-(1-adamantoyl)indole (other name: AB-001);
  - (8-quinolinyl)(1-pentylindol-3-yl)carboxylate (other name: PB-22);

- 1229 (8-quinoliny)(1-(5-fluoropentyl)indol-3-yl)carboxylate (other name: 5-fluoro-PB-22);  
 1230 (8-quinoliny)(1-cyclohexylmethyl-indol-3-yl)carboxylate (other name: BB-22);  
 1231 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide (other name: AB-PINACA);  
 1232 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide (other name:  
 1233 AB-FUBINACA);  
 1234 1-(5-fluoropentyl)-3-(1-naphthoyl)indazole (other name: THJ-2201);  
 1235 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide (other name:  
 1236 ADB-PINACA);  
 1237 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (other name:  
 1238 AB-CHMINACA);  
 1239 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide (other name:  
 1240 5-fluoro-AB-PINACA);  
 1241 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (other  
 1242 names: ADB-CHMINACA, MAB-CHMINACA);  
 1243 Methyl 2-((1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (other name:  
 1244 5-fluoro-AMB);  
 1245 1-naphthalenyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (other name: NM-2201);  
 1246 1-(4-fluorobenzyl)-3-(2,2,3,3-tetramethylcyclopropylmethanone)indole (other name: FUB-144);  
 1247 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole (other name MAM-2201);  
 1248 N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide  
 1249 (other name: ADB-FUBINACA);  
 1250 Methyl 2-[1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other  
 1251 name: MDMB-FUBINACA);  
 1252 Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other names:  
 1253 5-fluoro-ADB, 5-Fluoro-MDMB-PINACA);  
 1254 Methyl 2-((1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl)amino)-3-methylbutanoate (other  
 1255 names: AMB-FUBINACA, FUB-AMB);  
 1256 N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (other name: FUB-AKB48)  
 1257 N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (other name: 5F-AKB48);  
 1258 Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate (other name: SDB-005);  
 1259 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide (other name:  
 1260 AB-CHMICA);  
 1261 1-pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide (other name: SDB-006);  
 1262 Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (other name: FUB-PB-22);  
 1263 Methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (other name: MMB-CHMICA);  
 1264 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide (other name:  
 1265 5-fluoro-ADB-PINACA).
- 1266 2. That §§ 3.2-4114.1 and 3.2-4117 of the Code of Virginia are repealed.  
 1267 3. That the Virginia Department of Agriculture and Consumer Services (the Department), by  
 1268 December 1, 2019, shall report to the General Assembly on (i) the fiscal impact of the growth of  
 1269 the industrial hemp industry in Virginia upon the Department's registration program and (ii) any  
 1270 need to alter the registration fee charged by the Department.  
 1271 4. That the Virginia Department of Agriculture and Consumer Services, by December 1, 2019,  
 1272 shall report to the Chairmen of the House Committee on Agriculture, Chesapeake and Natural  
 1273 Resources and the Senate Committee on Agriculture, Conservation and Natural Resources on the  
 1274 viability of markets for Virginia industrial hemp growers, the types of products made from  
 1275 industrial hemp that can be produced in Virginia, and the economic benefits and costs of  
 1276 production of such products.  
 1277 5. That the Secretary of Agriculture and Forestry and the Secretary of Health and Human  
 1278 Resources shall, by November 1, 2019, report to the General Assembly on the appropriate  
 1279 standards, if any, for the production of an oil with a tetrahydrocannabinol concentration of no  
 1280 greater than 0.3 percent that is derived from industrial hemp, as defined in § 3.2-4112 of the Code  
 1281 of Virginia as amended by this act.  
 1282 6. That the provisions of this act may result in a net increase in periods of imprisonment or  
 1283 commitment. Pursuant to § 30-19.1:4 of the Code of Virginia, the estimated amount of the  
 1284 necessary appropriation is \$0 for periods of imprisonment in state adult correctional facilities and  
 1285 \$0 for periods of commitment to the custody of the Department of Juvenile Justice.  
 1286 7. That an emergency exists and this act is in force from its passage.